Anatara Lifesciences (ASX:ANR) today released its Appendix 4D financial report for the half year ending 31st December 2017.

Highlights from the period include:

- Global animal health company, Zoetis Inc, exercising its option to negotiate a commercial agreement for the worldwide development, distribution and marketing of Detach(R).

- Establishing an experienced veterinary team focused on launching Detach(R) into the anti-diarrhoeal therapeutic pig market.

- Developing a proprietary dosing device for the optimal delivery of Detach(R) by pig farmers

- Presenting at the Australasian Pig Science Association (APSA) Conference - highlighting the comparable efficacy of Detach(R) to in-feed Zinc Oxide

- Increasing focus on human opportunities through the development of proprietary products for the management of diarrhoea associated with gastrointestinal disorders

To view the full report, please visit:
http://abnnewswire.net/lnk/155QR045


About Anatara Lifesciences Limited

Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

    

Contact

Investor inquiries:
Dr Mel Bridges
Chairman & CEO, Anatara Lifesciences
Phone: +61-413-051-600
Email: mbridges@anatara.com

Media inquiries:
Jane Lowe
Managing Director, IR Department
Phone: +61-411-117-774
Email: jane.lowe@irdepartment.com.au



Link: Half Yearly Report and Accounts


Related Companies

Anatara Lifesciences Limited


Related Industry Topics: